POLYMED Poly Medicure Q2 FY26 results (Jul–Sep 2025) and concall
Poly Medicure delivered a steady Q2 performance characterized by robust domestic growth and strategic inorganic expansion in Europe. While international markets faced headwinds from Chinese competition and regulatory shifts, the company successfully closed two acquisitions to bolster its Cardiology and Orthopedic portfolios. Management is pivoting away from low-margin government business to focus on private domestic markets and high-value exports, guiding for a significant revenue ramp-up in H2 FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 5.7%, net profit up 5.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 420 | 424 | 441 | 403 | 444 +6% |
| EBITDA | 115 | 114 | 119 | 106 | 115 +0% |
| Net profit | 87 | 85 | 92 | 93 | 92 +6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
